Detalhe da pesquisa
1.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37285865
2.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36273926
3.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34103386
4.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32359490
5.
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol
; 159(1): 101-111, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32861537
6.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Artigo
Inglês
| MEDLINE | ID: mdl-28916367
7.
Clinical and serological resolution of pembrolizumab associated Sjögren's syndrome: long-term follow-up.
Rheumatology (Oxford)
; 61(1): e22-e24, 2021 12 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34508566
8.
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Lancet Oncol
; 16(6): 686-94, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25981814
9.
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Lancet Oncol
; 16(3): 338-48, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25701170
10.
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Future Oncol
; 10(2): 219-31, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24490608
11.
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.
Int J Gynecol Cancer
; 24(9 Suppl 3): S42-7, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25341579
12.
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nat Med
; 30(1): 257-264, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38049622
13.
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Eur Urol
; 83(4): 320-328, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35654659
14.
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Eur Urol
; 83(1): 15-26, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36055895
15.
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
Eur Urol Oncol
; 2023 Nov 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37940446
16.
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
J Clin Oncol
; 41(22): 3839-3850, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37290035
17.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
N Engl J Med
; 361(2): 123-34, 2009 Jul 09.
Artigo
Inglês
| MEDLINE | ID: mdl-19553641
18.
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Cancer Med
; 10(20): 7162-7173, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34549539
19.
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
J Clin Oncol
; 38(30): 3494-3505, 2020 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-32840418
20.
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nat Med
; 30(5): 1505, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38297094